X
Pharma Advancement
  • Home
  • Articles
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development
    Clinical Development

    AI Revolutionizing Drug Discovery and Clinical Development

    Drug-Development

    China’s Super Me-Too Drug Development: A New Pharma Frontier

    Omics Based Clinical Trials

    Asia Pacific Omics-Based Clinical Trials Market Growth

    AstraZeneca Eyes Acquisition To Develop Cell Therapies

    Advanced Instruments All Set To Merge With Nova Biomedical

    Taiho Pharmaceutical Buys Araris Biotech AG For $740 Million

    Oracle Wins the Asia Pacific Biopharma Excellence Awards

    Continuous Manufacturing is Improving Biopharma Production

    AI in Drug Commercialization Market to Grow CAGR 24% by 2032

  • Manufacturing
  • Supply Chain
  • Facilities
  • Insights
  • Events
  • Contact Us
No Result
View All Result
  • Home
  • Articles
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development
    Clinical Development

    AI Revolutionizing Drug Discovery and Clinical Development

    Drug-Development

    China’s Super Me-Too Drug Development: A New Pharma Frontier

    Omics Based Clinical Trials

    Asia Pacific Omics-Based Clinical Trials Market Growth

    AstraZeneca Eyes Acquisition To Develop Cell Therapies

    Advanced Instruments All Set To Merge With Nova Biomedical

    Taiho Pharmaceutical Buys Araris Biotech AG For $740 Million

    Oracle Wins the Asia Pacific Biopharma Excellence Awards

    Continuous Manufacturing is Improving Biopharma Production

    AI in Drug Commercialization Market to Grow CAGR 24% by 2032

  • Manufacturing
  • Supply Chain
  • Facilities
  • Insights
  • Events
  • Contact Us
No Result
View All Result
Pharma Advancement
No Result
View All Result
Home Europe

Vivalis R&D Facility

Yuvraj_pawp by Yuvraj_pawp
8th August 2014
in Europe, Projects

Vivalis opened a new R&D facility in Saint-Herblain, Nantes, France on 28 June 2010. The facility, located adjacent to its existing bio-production facility, has been designed to accommodate all R&D teams at one site. It has been constructed at an investment of approximately €6.5m, which includes €5.5m for the building and approximately €1m for the equipment.
The new facility will allow Vivalis to fast-track its development projects and simultaneously provide its employees with a better working environment. In comparison to the existing cGMP facility, the new facility is designed to consume 25% less energy.

Facility

The new facility is spread over 3,300m² and accommodates state-of-the-art cell biology research and discovery laboratories. It is installed with biological research equipment for virology, molecular biology, process development and activities related to drug screening.

The R&D activities were earlier carried out within Vivalis’ 2500m² cGMP production facility, also located in Saint-Herblain, Nantes, France. Opened in 2005, the facility included a separate unit dedicated for R&D activities. The facility additionally accommodates three separate multi-purpose suites that are equipped with up to 100l bioreactors. The suites conduct manufacturing of biologics in EB66 and CHO cells. The facility also houses a pharmaceutical filling room.

“The new facility will derive EB66 cell lines following the cGLP principles.”

Production

The new facility will derive EB66 cell lines following the cGLP principles. Laboratories dedicated for cell biology research will conduct isolation, culture, and expansion of animal embryonic cells. EB66 cell lines are produced for vaccines as well as proteins. The EB66 cells for vaccines have the ability to replace the embryonated eggs or chicken embryo fibroblats (CEF) for the industrial production of several human and animal vaccine systems.

The discovery laboratories will perform research for anti-viral small molecules using the 3D-screen platform. The 3D-screen technology allows new chemical bodies to be identified in the framework of collaborative research and development partnerships in the field of anti-virals. The laboratories will additionally conduct research and development activities associated with the optimisation of processes for the production of recombinant proteins on the EB66 platform.

Vivalis EBx technology

The facility will derive EB66 cell lines, using the company’s patented EBx technology. Vivalis EBx technology platform allows production of both vaccine and protein under both research and commercial licenses. Besides being cost effective, the technology is simple, fast, more hygienic and a more robust system.

Using the technology, duck embryonic stem cells are used to produce substrate cell lines. The process starts with separation of the avian embryos at the developmental stage. This is followed by suspension of the avian embryonic stem (ES cells), derived by dissociation of avian embryos in a basal culture medium. The medium is supplemented by growth factors and foetal calf serum. The suspension of ES cells obtained is seeded on a layer of feeder cells and further cultured.

“The cells produced demonstrate favourable characteristics including genetic stability.”

Another round of culturing is carried out after all the growth factors are withdrawn. To get a complete withdrawal of feeder cells, the concentration of feeder cells is gradually reduced after which the ES cells are cultured again.

Likewise the ES cells are cultured after the animal serum is gradually reduced.

At the end of this process, the adherent avian EBx cell lines are derived, which may then be further adapted to suspension culture conditions.

The cells produced demonstrate favourable characteristics including genetic stability, diploid karyotype, indefinite cell proliferation capability and strong expression of ES specific markers including telomerase.

Besides allowing the cells to be cultured in serum free media, the technology allows rapid proliferation in bioreactors at high cell densities as suspension cells.

Financing

The facility has been financed by a combination of sources including state and local bodies. Approximately €2.4m has been contributed by DIACT, Region Pays de Loire, Departement of Loire Atlantique and Nantes Métropole. Bank loans amount to €2.5m while the remaining €1.6m has been sourced by Vivalis internally.

Tags: Europe
Previous Post

Roche Pharmaceutical Manufacturing Plant

Next Post

UCB Biologics Pilot Plant, Braine-l'Alleud

Related Posts

Europe

Pharma Sector Seeks Seamless EU Medical Device Rules

24th March 2025
Pharmapack 2023 a pivotal moment for sustainability in drug delivery and packaging
Europe

Pharmapack 2023 a pivotal moment for sustainability in drug delivery and packaging

3rd March 2023
Dr Reddy's Lab gets DCGI nod for Sputnik Phase 2 & 3 trials
Europe

RDIF and Minapharm Agree to Produce over 40 Million Doses of the Sputnik V Vaccine in Egypt

26th April 2021
Sputnik V: World's First COVID-19 Vaccine Now Available to Public in Russia
Europe

Sputnik V: World’s First COVID-19 Vaccine Now Available to Public in Russia

26th September 2020
AstraZeneca agrees to supply Europe with 400 million doses of COVID-19 vaccine
Europe

Valneva Announces Major COVID-19 Vaccine Partnership with U.K. Government

21st September 2020
Europe

Pharmintech 2019: Big increase in International Participation Expected

18th November 2018
Next Post

UCB Biologics Pilot Plant, Braine-l'Alleud

Qucik Links

  • Drug Development
  • Manufacturing
  • News
  • Events & Conferences
  • Newsletter Archive
Pharma Advancement

About Us

Pharma Advancement is a leading Pharma information centric website. On one side Pharmaadvancement.com has established itself as one of the most efficient and comprehensive source of Pharma information online, dedicated to providing decision makers in all the Pharma industry sectors with reliable, accurate and useful insights into happenings in the Pharma sector.

Subscribe Us

System

  • Search
  • Sitemap
  • RSS Feed

Resources

  • Advertise with us
  • Contact Us
  • Download Mediapack
  • Newsletters Archive

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

No Result
View All Result
  • Home
  • Articles
  • Drug Development
  • Manufacturing
  • Supply Chain
  • Facilities
  • Insights
  • Events
  • Contact Us

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

Login to your account below

Forgotten Password?

Fill the forms bellow to register

All fields are required. Log In

Retrieve your password

Please enter your username or email address to reset your password.

Log In